Clinical trials: Fatty Liver Disease
Non Alcoholic Fatty Liver Disease, Type 2 Diabetes
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes
The main objective of this study is to analyze the pathophysiological implications of glucagon and the incretin hormones in patients with liver disease (Non alcoholic fatty liver disease (NAFLD) or cirrhosis) with and without…
- Conditions
- Non Alcoholic Fatty Liver Disease, Type 2 Diabetes, Liver Cirrhosis
- Trial name
- NCT01492283
- Testing
- OGTT, IIGI
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type2 Diabetes, Non-Alcoholic Fatty Liver Disease
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases
- Trial name
- NCT03910361
- Testing
- Evogliptin, Pioglitazone
- Where
- 7 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- Dong-A ST Co., Ltd.
NAFLD - Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Hepatic and Cardiac Metabolic Flexibility in Subjects With T2DM With and Without NAFLD
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis.
- Trial name
- NCT04698486
- Testing
- Hyperinsulinemic euglycaemic clamp
- Where
- Denmark
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Non-Alcoholic Fatty Liver Disease
Effect of Omega-3 PUFA Supplementation in NAFLD Patients
The purpose of this study is to determine whether dietary supplementation with omega-3 polyunsaturated fatty acids will decrease the amount of fat in liver.
- Trial name
- NCT00230113
- Testing
- Fish oil, Safflower oil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NAFLD
NAFLD in Diabetes Type 2 in Primary Care
The EPSONIP (Evaluating Prevalence and Severity Of NAFLD In Primary care) trial is a longitudinal cohort study of patients with T2DM recruited from primary health care centers in Östergötland, Sweden.
- Trial name
- EPSONIP (NCT03864510)
- Where
- 2 sites in Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
Brain Death, Liver Steatosis
"LiverColor": Machine Learning in Liver Photographs
The main goal of this project is to create a machine learning model in order to quantify liver steatosis in liver donor faster, more objective and reliable than histological analysis and surgeons point-of-view.
- Trial name
- NCT05202886
- Testing
- Liver from deceased donors
- Where
- Spain
- Volunteers
- 246 people
- Sponsor
- Hospital Vall d'Hebron
Nonalcoholic Fatty Liver Disease, HIV
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
A subset of patients with NAFLD that have not been extensively studied are those infected with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for NAFLD or NASH.
- Trial name
- ARRIVE (NCT02684591)
- Testing
- Aramchol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Non Alcoholic Fatty Liver Disease
A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease
Sidekick Health has developed a digital behavioral change program (SK-241) specifically designed for people with metabolic derangements and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05426382
- Testing
- A digital care solution for patients with NAFLD
- Where
- 2 sites in Iceland
- Volunteers
- 38 people
- Sponsor
- Sidekick Health
Growth Hormone, Recombinant, Fatty Liver
The Effect of Growth Hormone Replacement on Liver Fat
We will examine a cohort of growth hormone deficient adults starting growth hormone (GH) replacement. The purpose of this study is to determine whether GH replacement reduces the fat content of the liver.
- Trial name
- NCT00774579
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Imperial College London
Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD)
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients
The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease (ALD), Liver Fibrosis
- Trial name
- SOPRANO (NCT05699018)
- Testing
- eLIFT
- Where
- 13 sites in France
- Volunteers
- 1,788 people
- Sponsor
- University Hospital, Angers
Non-alcoholic Fatty Liver Disease
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.
To further clarify the role of sequence polymorphism in patatin-like phospholipid domain containing protein 3 in the development of nonalcoholic fatty liver disease.
- Trial name
- NCT04104282
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Xijing Hospital
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus
Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.
Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement…
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus, Hypertension, Hyperlipidaemia
- Trial name
- NCT07025980
- Testing
- The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS
- Where
- Croatia
- Volunteers
- 114 people
- Sponsor
- Eva Cubric
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
Acquired immunodeficiency syndrome (AIDS) remains a severe global infectious disease, with over 38 million people living with HIV and around 35 million cumulative deaths worldwide by 2023; approximately 1.24 million HIV-positive…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fibrosis, HIV/AIDS
- Trial name
- NCT05330923
- Testing
- Liver Quantitative Ultrasound
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
NAFLD in Adolescents and Young Adults With PCOS
This project focuses on an at-risk adolescent and young adult population who may gain long-term health benefits from detection of risk factors at a young age.
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02506946
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Columbia University
Obstructive Sleep Apnea, Non-alcoholic Fatty Liver
Free Walking Exercise in Obstructive Sleep Apnea Patients With Non-alcoholic Fatty Liver
Research evaluating the impact of continuous positive airway pressure (CPAP) \& walking exercise on fatigue severity, liver enzymes and sleeping quality in patients with non-alcoholic fatty liver disease who also have obstructive…
- Trial name
- NCT06508190
- Testing
- continuous positive airway pressure, free walking exercise and continuous positive airway pressure
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ahram Canadian University
Non-Alcoholic Fatty Liver Disease
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Trial name
- SHIELD (NCT06355310)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Liver Disease
Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients
Non alcoholic fatty liver diseases (NAFLD) are represented by two main pathological conditions, hepatic steatosis (HS) and non alcoholic steatohepatitis (NASH), which are characterized by the accumulation of fat in the liver.
- Trial name
- NCT00844779
- Testing
- Bariatric surgery, cholecystectomy or benign liver tumor removal
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Strasbourg, France
Nonalcoholic Steatohepatitis, Osteoarthritis
FTIH Study of ECC0509 in Healthy Volunteers
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in…
- Trial name
- NCT05012423
- Testing
- ECC0509
- Where
- Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Eccogene
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05979779
- Testing
- HU6
- Where
- 20 sites in United States
- Volunteers
- 219 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.